Media Contact:
Alison Guzzio
484-459-3243
Alison.guzzio@thirdlaw.tech
Philadelphia, PA – May 7, 2025 – ThirdLaw Molecular Inc., a pioneering drug discovery company, today announced that DJ Bernsteel, PhD, will present groundbreaking research on screening a 4.5 billion-member DNA-encoded library to identify protein binders at the Society for Laboratory Automation and Screening (SLAS) Europe 2025 conference in Hamburg, Germany, from May 20-22, 2025.
The presentation has been selected as part of the prestigious Innovation AveNEW program, an award that recognizes disruptive scientific innovation and provides full sponsorship for participation. “At ThirdLaw Molecular, we are redefining drug discovery with our breakthrough Spiroligomer™ platform, offering a new therapeutic modality that bridges the best of small molecules, biologics, and cyclic peptides. With our powerful SYMBA-DEL screening engine and a growing pipeline of validated hits, we are poised to unlock novel treatments for challenging targets. We look forward to sharing our latest advancements and collaborating with partners to accelerate the next generation of precision therapeutics,” stated Bernsteel.
About DJ Bernsteel, PhD
Dr. Bernsteel brings over 15 years of multidisciplinary research experience in glycobiology, neuroscience, biochemistry, and pharmacology. His expertise spans biochemical, molecular biology, cell-based, and analytical techniques, including high-performance liquid chromatography (HPLC), molecular cloning, qRT-PCR, protein expression and purification, flow cytometry, and lentivirus production. He has also designed novel assays and systems to optimize scientific approaches.
Dr. Bernsteel’s PhD research focused on a sugar modification linked to cancer, human development, and neurological diseases. At ThirdLaw Molecular, he leads efforts in DNA-encoded library screening to identify potential candidates for development as therapeutics and diagnostic tests, utilizing cutting-edge molecular tools to advance precision medicine.
About ThirdLaw Molecular
Founded in 2020 by Dr. Christian Schafmeister, a Professor of Chemistry at Temple University, ThirdLaw Molecular is at the forefront of therapeutic innovation. Initial funding from the Department of Defense supported the development of this transformative biotechnology, which is poised to redefine the future of medicine. With its Spiroligomer™ platform, ThirdLaw Molecular is pioneering the next generation of targeted therapeutics, unlocking new possibilities in the diagnosis and treatment of diseases. For more information, please visit thirdlawtx.com.